- Home
- WSHP vs BCYC Comparison
WSHP vs BCYC Comparison
Compare WSHP & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WSHP | BCYC |
|---|---|---|
| Founded | 2021 | 2009 |
| Country | British Virgin Islands | United Kingdom |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 487.8M | 360.7M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | WSHP | BCYC |
|---|---|---|
| Price | $5.81 | $5.06 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $13.90 |
| AVG Volume (30 Days) | 274.3K | ★ 574.3K |
| Earning Date | 01-01-0001 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.95 | $4.24 |
| 52 Week High | $250.00 | $9.55 |
Technical Indicators
Market Signals| Indicator | WSHP | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 33.54 | 53.49 |
| Support Level | $4.95 | $5.03 |
| Resistance Level | $117.73 | $5.90 |
| Average True Range (ATR) | 1.08 | 0.26 |
| MACD | 1.13 | 0.09 |
| Stochastic Oscillator | 25.59 | 75.68 |
Price Performance
Historical ComparisonAbout WSHP WeShop Holdings Limited Class A Ordinary Shares
WeShop Holdings Ltd is a community owned social commerce platform offering shoppers shares in the Company every time customers make a purchase, recommend a product or refer a new member. WeShop earns revenues from advertising on their platform and commissions on the sales through the platform.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.